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Coronary restenosis is a reparath'e response to arterial injury 
during angioplasty, and remains a major clinical problem. The 
reasons for treatment failures likely stem from our incomplete 
understanding of the cellular mechanisms in restenotic neointimal 
formation. 
Restenosis is thought to result from migration and replication 
of medial smooth muscle cells to form an obstructh'e neointima, a 
concept neither obsened nor demonstrated in humans. An alter-
nath'e hypothesis for restenosis is based on obsenations in the 
porcine coronary injury model. In this model, there are three 
cellular stages in neointimal formation: thrombotic (stage I), 
cellular recruitment (stage II) and proliferative (stage III). The 
thrombotic stage occurs early and consists of platelets, fibrin and 
Coronary artery restenosis remains a major limitation of 
balloon angioplasty and all other percutaneous revascular-
ization procedures. It is the Achilles' heel of angioplasty, 
resulting in repeat procedures, increased morbidity and 
escalating medical costs. Although the incidence, timing, 
clinical and anatomic associations of restenosis have been 
studied in depth (1-5), no therapy consistently prevents this 
difficult problem. 
None of the many theories explaining the mechanisms of 
restenosis has been scientifically validated either in humans 
or in animal models. A diverse array of failed therapies 
(pharmacologic and technologic) have been based on these 
theories. The purpose of this review is to examine the 
possible reasons for these treatment failures and to propose 
an alternative hypothesis for the cellular mechanisms of 
restenosis. This alternative hypothesis, if proved correct, 
may be useful in developing more effective therapies. 
Why have we failed to soh'e the restenosis problem? Mo'st 
pharmacologic agents (Table 1) have failed to reduce the 
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red blood cells accumulating at the wssel injury site. In the 
recruitment stage, the mural thrombus itself dewlops an endothe-
lium, followed by a mononuclear leukocytic infiltrate beginning on 
the lumen side of the ,'essel. In the proliferative stage, a "cap" of 
actin.posith·e cells forms on the lumen surface and progressinly 
thickens. These cells do not arise from media a~ the injury site. 
Extracellular matrix secretion and additional recruitment likely 
add to neointimal volume during this phase. 
Thrombus assumes a major role in restenosis by providing an 
absorbable matrix into which smooth muscle cells proliferate. 
Further studies are needed to ,'alidate or modify this hypothesis. 
(J Am Coli CardioI1992;20:1284-93) 
restenosis rate in clinical trials. These drugs span a broad 
spectrum of pharmacologic action, representing many drug 
classes. Failure of these trials implies one of the following: 
1) a truly effective agent has not yet been tested, 2) one or 
more potentially effective agents have been tested, but in 
incorrect dosage or timing, 3) more than a single agent is 
needed, or 4) the restenotic response cannot be effectively 
modified by systemic therapy at drug levels that are tolerable 
in humans. It is noteworthy that all pharmacologic trials to 
date have tested systemic treatment for a problem localized 
to a small coronary artery segment. 
Prior pharmacologic trial~ against restenosis have been 
based on the plausible but largely unproved hypothesis that 
obstructive neointima results from uncontrolled medial 
smooth muscle cell proliferation at the arterial injury site. 
This concept is shown schematically in Figure I and has 
been summarized previously (28,29). In this theory, medial 
smooth muscle cells at the site of the injured artery respond 
by uncontrolled migration, proliferation and extracellular 
matrix synthesis. Mural thrombus caused by the injury may 
contribute cytokines, chemoattractants and growth factors 
that initiate and sustain the neointimal growth process (30). 
The final result of uncontrolled growth is a space-occupying 
lesion that impinges on the arterial lumen. 
This hypothesis does not originate from direct observa-
tion; instead, it is inferred from isolated observations in 
humans and animal models. Because prior approaches to 
restenosis based on this hypothesis have failed, the validity 
of the hypothesis itself should be questioned. The individual 
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Table 1. Pharmacologic Results in Human Restenosis Trials 
Agent (study» Result 
Aspirin 
Thornton, 1984 (6) Negative 
Ellis, 1987 (7) Negative 
Mufson, 1988 (8) Negative 
Aspirin/dipyridamole 
Schwartz, 1988 (9) Negative 
Thromboxane blockade 
Finci, 1989 (10) Negative 
Coumadin 
Thornton, 1984 (6) Negative 
Urban, 1988 (11) Negative 
Heparin 
Ellis, 1989 (12) Negative 
Corticosteroids 
Pepine, 1990 (13) Negative 
Fish oil 
Grigg, 1989 (14) Negative 
Dehmer, 1988 (15) Effective 
Reis, 1989, 1990 (16-18) Negative 
Milner, 1989 (19) Negative 
Nye, 1990 (20) Effective 
Olsson, 1989 (21) Effective 
Lipid lowering 
Hollman, 1989 (22) Negative 
Sahni, 1991 (23) Effective 
Calcium channel blockade 
Corcos, 1985 (24) Negative 
Whitworth, 1986 (25) Negative 
Prostacydin 
Knudtson, 1990 (26) Negative 
Angiotensin·converting enzyme 
inhibitors 
Serruys, 1992 (27) Negative 
'Studies are identified by first author, year of publication (reference 
number). 
components of this conventional hypothesis will thus be 
critically examined. 
Proposed Mechanisms of Restenosis 
Thrombus at the injury site. Thrombus has long been 
implicated in the formation of neointima (31-37), At sites of 
acute arterial injury. large aggregations of platelets ("white 
thrombus") and fibrin with entrapped red blood cells are 
routinely found (36,38). These thrombi contain attractants 
and mitogens for smooth muscle cells. Because the relative 
importance of platelets, thrombin and fibrin to restenosis is 
unclear, therapeutic approaches based on anyone thrombus 
component may not be sufficient to successfully limit neoin-
timal formation. Furthermore, the quantitative relation be-
tween thrombus volume and ultimate neointimal volume is 
unknown, and the relative contribution of thrombus to 
neointimal volume has not been addressed. That clinical 
trials of anticoagulants (aspirin, dipyridamole, heparin and 
coumadin) have failed may not be surprising in view of their 
SCHWARTZ ET AL. 1285 
PATHOPHYSIOLOGY OF RESTENOSIS 
Figure 1. Current paradigm for neointimal formation. The current 
theory holds that smooth muscle cells of the injured media migrate 
and proliferate into a mass of tissue that subsequently causes vessel 
stenosis. In the schematized concept shown here, stenosis occurs at 
sites where the internal elastic lamina has been ruptured. 
comparatively weak and nonspecific activity at the dosages 
used. Patients with clinically therapeutic anticoagulation 
must maintain some thrombotic capability (39) so that mural 
thrombus is probablY present at the angioplasty site even in 
such patients. 
The relation of platelets, thrombin and other components 
of the thrombotic process to neointimal formation should be 
better understood before substantial time and money are 
invested in new clinical trials. More potent agents (for 
example, hirudin, platelet fibrinogen receptor antagonists, 
factor Xa inhibitors) will shortly be available and will un-
doubtedly be subjected to extensive investigation (40,41). 
One important question regarding thrombus and resteno-
sis is whether the volume of mural thrombus relates to the 
ultimate volume of healed neointima. Liu et al. (28) sug-
gested that thrombus volume may 1I0t be a major source of 
neointimal volume, but there is little direct histopathologic 
evidence to answer this question. Does a proportionality 
exist so that reduction of platelets and fibrin will correspond-
ingly reduce neointima, or must all thrombus be eliminated 
to limit neointimal formation? Is a monolayer of platelets 
sufficient to cause a clinically significant restenotic lesion, as 
suggested by others (42)? These questions hold substantial 
implications for treatment because complete local elimina-
tion of thrombus may be neither feasible nor safe when 
achieved through systemic anticoagulation. 
Growth factors. Biochemical growth factors are often 
implicated in the rapid formation of neointimal hyperplasia 
after arterial injury (43,44). Although many growth factors 
have been characterized (Table 2), little is known of their 
direct role in the genesis of restenotic neointima. Which 
growth factors have major, and which have minor effects? 
Do undiscovered growth factors playa key role in resteno-
sis? Will it be necessary to inhibit more than one factor to 
reduce neointima? Although the principle of growth factors 
inciting smooth muscle cell replication enjoys widespread 
acceptance, it entails assumptions that have not been ob-
served or confirmed in any in vivo system. Better under-
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Table 2. Growth Factors and Cytokines Implicated in Restenosis 
Platelet-derived growth factor 
Basic fibroblast growth factor 
Insulin-like growth factor 
Transforming growth factors - f31 and - f37. 
Interleukin-l, interleukin-4, interleukin-6 
Heparin binding growth factor-! 
Reference 
No. 
43,45,46 
47,48 
49-52 
53-55 
56-61 
62 
standing of growth factors and their role in restenosis (45) 
may permit the design of specific therapies, but a complete 
understanding of all growth factors prominent in restenosis 
is not likely in the near future. 
Extracellular matrix. The importance of extracellular 
matrix in the restenotic process may be inferred from direct 
examination of neointima. Neointima is generally hypocel-
lular fibrous tissue, predominantly glycosaminoglycans and 
various forms of collagen. Figure 2 shows an example of 
restenotic neointima. Measurements of human neointima in 
our laboratory show an average of 715 cells in a volume of 
Figure 2. Human neointima is mostly extracellular matrix (see 
calculations in text). Hematoxylin-eosin X300, reduced by 25%. 
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3.28 X 10-3 mm3, or 2.18 x 105 cells/mm3 • Typically, the 
volume of one neointimal cell (nucleus cytoplasm) is 
approximately 512 ,um3• Thus in of neointima, the 
volume actually comprising cells is 2.18 x cells x 
512 ,um3/ceU, or 0.111 mm3• Thus, cellular components 
constitute only about 11% of neointimal volume, and the 
remainder is extracellular matrix. 
Given the abundance of extracellular matrix in restenotic 
lesions, one restenosis treatment strategy may be to reduce 
the matrix volume surrounding each cell. A substantial 
reduction in neointimal volume might be obtained even if the 
absolute number of cells secreting matrix were unchanged. 
A net decrease in stenosis would without the need to 
inhibit smooth muscle cell migration or proliferation. 
Growth factor inhibition may contribute to this strategy 
because some growth factors (49,53) have been implicated in 
matrix synthesis. 
The smooth muscle cell. Both secretory and contractile 
smooth muscle cell phenotypes are considered to play the 
central role in restenosis. Most therapies under consider-
ation involve inhibition of smooth muscle cell function. 
These strategies propose to reduce migration, proliferation 
or matrix synthesis by the smooth muscle cell and are briefly 
described later. 
Angiotensin-converting enzyme inhibition and restenosis. 
Reports by Powell et al. (63) and others (64-66) demon-
strated a substantial reduction of neointimal thickness 
in balloon-injured rat carotid arteries by angiotensin-
converting enzyme inhibition. The arterial wall contains 
proteases capable of the conversion of angiotensin I to 
angiotensin II. Angiotensin II is not a known mitogen, but it 
does stimulate protein synthesis (64). Inhibition of extracel-
lular matrix formation by angiotensin-converting enzyme 
inhibitors may be one reason for the successful use of these 
agents in the rat model. 
Great interest after early reports led to several clinical 
trials of angiotensin-converting enzyme inhibitors. How-
ever, data from the European MERCATOR trial with oral 
cilazapril suggest little benefit at the dosing and schedules 
used (27). 
Lipids and restenosis. The importance of serum choles-
terol and other lipids in restenosis remains unclear. Results 
of several lipid-lowering restenosis trials have been conflict-
ing. No definitive evidence yet exists for the efficacy of lipid 
lowering after percutaneous transluminal coronary angio-
plasty to prevent restenosis (15,16,20,23). At least two large 
randomized trials are in progress using the 3-hydroxy-3-
methyl-glutaryl coenzyme A reductase lovastatin. 
It is unclear how serum lipid reduction prevent resten-
osis, although toxicity of lipids to endothelium is one possi-
bility. 
Antimetabolites and antimitotic agents. Pharmacologic 
prevention of smooth muscle cell proliferation has been the 
rationale for using antimetabolite agents in restenosis. Meth-
otrexate and azathioprine were unsuccessful in animal mod-
els (67,68). Anecdotal data on unsuccessful experiences with 
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Table 3. Animal Restenosis Models 
Species Vessel 
Rat Carotid 
Rabbit Iliac 
Rabbit Ear 
Pig Coronary 
Pig Carotid 
Reference 
No. 
(42.74.75.78) 
(40.79.80) 
(81) 
(82) 
(33.83) 
methotrexate in humans also exist (Hinohara, personal com-
munication, November 1991). Other potent toxins are under 
active consideration (69), as are growth inhibitors such as 
somatostatin analogues (70-73). 
Current concepts of restenotic cellular mechanisms thus 
focus on hypotheses in which arterial smooth muscle cells at 
the medial injury site migrate to intima, proliferate and 
synthesize extracellular matrix in an uncontrolled manner. 
This sequence of events has not been observed in humans; 
thus, animal models have assumed paramount importance in 
the study of restenosis (74-77). 
Animal Restenosis Models: Problems 
or Solutions? 
At least five animal models of arterial injury restenosis 
are in current use (Table 3). Animal models have two roles in 
restenosis research. The first is to test potential therapies 
before human trials. In this context, these models have been 
disappointing because many therapies that proved effective 
in these models failed in human studies. Many possible 
reasons exist for these frustrating failures. First, the patho-
physiologic response to arterial injury in an animal model 
may differ from that in humans. Cellular events in these 
models have not been correlated with comparable events in 
humans; thus, the limitations of these models at a cellular 
level remain unknown. Second, doses and drug effects from 
successful animal trials may not translate acceptably to 
humans. Third, many animal models utilize peripheral arter-
ies such as the iliac or carotid arteries, which are elastic 
vessels, as opposed to the epicardial coronary arteries, 
which are muscular. Also, definitions for successful treat-
ment in animal models frequently differ from thos,e of 
treatment defined clinically. Histopathologic measurements 
of neointimal thickening in animal arteries, for example, are 
frequently statistically significant but would not be detect-
able if measured angiographically. Finally, human restenosis 
occurs on an atherosclerotic substrate, substantially differ-
ent from the normal arteries used in most animal studies. 
Animal models also may be used to understand the 
cellular and molecular events of restenosis. Fewer than 70 
cases have been described in all published studies of patho-
logic findings after angioplasty in humans, including < 10 
cases in the critical early (I to 4 weeks) time periods. The 
time course of human restenotic neointimal formation thus 
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remains unknown because tissue has been obtained only 
from the very early (hours to days) or late stages of healing 
after dilation. Efforts should be directed toward better 
characterization of animal models to understand the forma-
tion of neointima. 
In summary, current animal models of restenosis have 
not been sufficiently well characterized to understand their 
limitations and relevance when applied to human angio-
plasty. The discrepant data from human and animal trials 
highlight our incomplete understanding of the restenosis 
process itself at both cellular and molecular levels. Standard-
ization of methodology in animal models is needed to better 
understand why these models fail to predict results of the 
same agents used in humans. 
Questions about the current restenosis hypothesis. Be-
cause most therapies based on the classic smooth muscle cell 
proliferation hypothesis have failed, the validity of this 
hypothesis should be questioned. Recent studies (84) in a 
porcine coronary injury model suggest a different sequence 
of events in the restenotic process that may be closer to the 
pathophysiology of restenosis in humans. 
Restenotic Neointimal Development: Stages in 
a Porcine Model 
Severe mechanical injury to the normal porcine coronary 
artery causes arterial stenosis from neointima identical his-
topathologically to human restenotic tissue. Three distinct, 
sequential cellular healing phases occur in this injury-
response model (Fig. 3 and 4). 
Stage I: thrombotic phase (Fig. 4A). The immediate re-
sponse to arterial injury in the porcine model is thrombus 
formation composed initially of aggregated platelets, fibrin 
and trapped erythrocytes. The platelet component ("white 
thrombus") occurs at the site of deep arterial injury. The 
fibrin and red cell component ("red thrombus") is attached 
to the densely aggregated platelets. 
Stage II: Cellular recruitment phase (Fig. 48). The next 
stage of healing comprises cellular recruitment into the 
thrombus itself. The first recruitment event is endothelial-
ization of the lumen (blood) surface of the thrombus, which 
occurs by 3 to 4 days. Recruitment of mononuclear leuko-
cytes follows endothelialization and consists of monocytes-
macrophages and lymphocytes. These monocytes and lym-
phocytes line the 111m en surface and are found migrating 
deep into the degenerating thrombus beneath the newly 
formed endothelium. The recruitment phase thus begins 
from the lumen (endothelial) surface of the thrombus mass 
rather than from deep medial regions of the injured vessel 
segment. 
Macrophages and lymphocytes are commonly found 
within the thrombotic mass and often are surrounded by a 
clear, fibrin-free zone. The macrophages secrete fibrinolytic 
enzymes that are probably responsible for resorption of 
thrombus (85). The cellular infiltrate and the thrombus itself 
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may be an abundant source of growth factors and chemoat-
tractant substances, facilitating and sustaining further cellu-
lar recruitment. 
Stage III: proliferative phase (Fig. 4C). Cellular prolifer-
ation occurs in the final arterial healing stage of the porcine 
model, approximately 7 to 9 days after injury. Beginning 
again at the Illmel! surface, cells that stain for alpha actin 
(possibly smooth muscle cells or myofibroblasts) colonize 
the degenerating thrombus mass. These cells initially form in 
a thin "cap" on the lumen surface just beneath the endothe-
lium. The cap thickens over time and appears to grow 
toward the site where medial injury initially occurred. Re-
sidual thrombus is resorbed as this cap thickens. Within the 
cap, the cellular architecture has the appearance of mature 
neointima. The healing process is complete when the all 
residual thrombus is resorbed and replaced by mature 
neointima. The mononuclear cell infiltration disappears at 
this late stage. Elaboration of extracellular matrix probably 
plays a role in this stage, increasing the neointimal volume 
through the amount of matrix produced. 
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Figure 3. Schematic illustration of the formation 
of neointima in the porcine coronary model. A, 
Acute arterial injury. The internal elastic lamina 
(lEL) and media have been lacerated. B, Within 
minutes after injury, acute thrombosis occurs at 
the site of injury, and in many cases spreads to 
nearby arterial sites. The thrombus has a mixed 
appearance, consisting of platelet-rich and fibrin-
rich regions. C, The thrombus becomes covered 
by a layer of endothelium at roughly 3 to 4 days. 
Shortly thereafter, there is infiltration of mono-
nuclear cells (from the lumen side first), consist-
ing of monocytes-macrophages and lymphocytes. 
Much fibrin and degenerating thrombus remain in 
the deeper regions. D, Smooth muscle cells begin 
to be seen roughly 6 days after injury. These cells 
stain positively for actin and appear first at the 
lilli/en surface to form a "cap" on the degener-
ating thrombotic mass that gradually thickens 
over time. Residual monocytes-macrophages and 
lymphocytes are still present in the deeper layers. 
E, The neointima is completely formed by about 
21 days. Residual fibrin and thrombus have been 
resorbed. The cap of panel D has progressively 
thickened to complete the healing process. Extra-
cellular matrix is probably being synthesized at 
this time, possibly increasing the severity of 
stenosis. EEL = external elastic lamina; RBC's 
= red blood cells. 
An Alternative Hypothesis for Restenosis 
A different mechanism for restenosis is suggested by this 
sequence of events in the pig. Prior work (31,86) implicating 
mural thrombus and neointima has not specifically impli-
cated a relation between thrombus volume and eventual 
neointimal volume. The distinction between platelet-rich and 
fibrin-rich thrombus has not been previously emphasized. In 
the current model, early endothelialization of the fibrin-rich 
thrombus itself, with subsequent smooth muscle cell coloni-
zation of the thrombus from the lumen surface, strongly 
suggests that much of the neointimal volume relates to the 
early fibrin-rich mural thrombus. These observations clearly 
implicate the fibrin thrombus as playing a central role in 
restenosis, different from the current paradigm of smooth 
muscle cell proliferation to create arterial obstruction 
through a tumor-like growth. 
If this same sequence also occurs in humans after angio-
plasty, novel conclusions and questions arise regarding 
possible therapy. Neointimal cells apparently do 1/01 come 
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Figure 4. Photomicrographs of the phases of neointimal 
development in the porcine coronary injury model. A, 
Thrombotic phase: thrombus lines the injured media. Plate-
let-rich and fibrin-rich regions are noted. The lumen of this 
artery is toward the left of the figure. This figure is from an 
animal killed 6 h after coronary artery injury. F = fibrin and 
red blood cells; M = media; PI = aggregated platelets and 
fibrin; (hematoxylin-eosin stain, x 750). B, Recruitment L 
phase: infiltration of monocytes/macrophages and lympho-
cytes. This cellular recruitment occurs first at the lumen 
border and proceeds toward media. The arterial lumen is at 
the top of figure, and at the bottom is degenerating throm-
bus. L = lumen; F = fibrin and red blood cells, degenerating 
thrombus (hematoxylin-eosin stain, x750). C, Proliferative 
phase: smooth muscle cell "capP forms on the thrombus. 
This cap occurs from the lumen surface first, progressively 
increasing in thickness toward media as thrombus is re-
sorbed. C = cap; F = degenerated fibrin and red blood cells; 
L = lumen; *site where wire was removed (hematoxylin-
eosin stain. x 500). 
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Figure 5 Oefl). Photomicrograph taken at an arterial site distant from 
stent injury. Note the thin, endothelialized neointima. Along the 
internal elastic lamina, medial cells seem to be transforming to a more 
rounded shape and migrating through breaks in the internal elastic 
lamina (arrows). The arterial lumen is at the right. E = endothelium; 
IEL = internal elastic lamina; M = media, NI = neointima. 
Hematoxylin-eosin x750, reduced by 35%. 
Figure 6 (below) A, Acute medial injury from microwave heating (see 
text) induced in a normal pig coronary artery 24 h before the animal's 
death. The endothelium is missing, probably because of heat and 
mechanical injury. Note the edematous media and pyknotic, cork-
screw-shaped nuclei indicating severe damage. Very few of these cells 
are likely to survive. L = lumen, M = media. Hematoxylin-eosin 
X380, reduced by 35%. B, Actin stain of a coronary artery site that 
underwent microwave heat injury 4 weeks before. The media is highly 
abnormal and quite hypocellular with very little actin affinity, proba-
bly because of the heat injury. Conversely, there is a thick neointima 
that avidly stains for actin. Such sections suggest that smooth muscle 
cells of the neointima may not originate at sites of arterial injury. In 
this case, the medial smooth muscle cells were severely damaged at 
the time of heating, and it is unlikely that they were responsible for 
forming the neointima. M = media (arrows show radial extent of the 
media); L = lumen, NI = neointima. Actin x254, reduced by 35%. 
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from media located at the injury site; the{r origin remains 
elusive. Do they come from media at the borders of the 
injury site? Figure 5 suggests this possibility. It shows the 
medial-neointimal interface at an arterial site distant from 
the injury location. These cells seem to be changing shape 
(and possibly phenotype), migrating through the internal 
elastic lamina into the subintimal space. From there they 
may continue migration into the "cap" seen directly above 
the injury location. 
Some of the neointimal cells may be myofibroblasts 
(87-91), cells known to heal injury in other tissues. From 
which cell line does the neointima arise, and what is its 
relation to the monocytes and lymphocytes present in the 
recruitment phase? 
Contrary to current understanding, the neointimal cell 
may not be primarily responsible for the volume of the 
restenotic lesion. The smooth muscle cell may be guilty only 
of infiltrating a preexisting thrombotic matrix. Support for 
this concept comes from a recent experiment in which 
microwave energy was delivered to normal swine coronary 
arteries by a custom balloon and antenna (Fig. 6). Heat from 
the microwave energy (80°C, 30 s) rapidly killed most medial 
smooth muscle cells at the balloon site. Yet 28 days later, the 
heated arteries exhibited a thick neointima staining posi-
tively for alpha actin. The media was atrophic, hypocellular 
and no longer stained for actin. Neointimal cells could not 
have come from the microwave balloon site because they 
were killed very early by local heat. Early clinical reports of 
laser balloon angioplasty (92) suggested that heat might 
cause local medial smooth muscle cell death, thus preventing 
restenosis. Yet subsequent studies found increased resteno-
sis rates in proportion to temperature. 
To summarize this alternative hypothesis: I) neointimal 
cells and "proliferation" are not primarily responsible for 
lumen obstruction but instead colonize a biodegradable 
fibrin matrix; 2) these cells do not necessarily arise from 
arterial media at the injury site; and 3) the neointimal cell 
heals the injury site from the lumen surface toward the 
adventitial surface. 
Clinical Observations Supporting the 
Alternative Hypothesis 
Support for this alternative hypothesis of restenosis 
mechanisms may be found in several clinical observations. 
Functional testing may predict patients who will develop 
restenosis (93-99). This phenomenon could be explained by 
the presence of early mural thrombus. Larger thrombus may 
cause early abnormal stress test or thallium results by 
stenoses at the angioplasty site. 
Implications of this alternative hypothesis. The proposed 
alternative hypothesis implies that thrombus is important in 
restenosis because it provides volume into which smooth 
muscle cells proliferate. If a strong relation exists between 
early thrombus volume and final neointimal volume, then 
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interventions to markedly limit mural thrombus after angio-
plasty might be an effective therapeutic strategy. One strat-
egy would be to severely limit mural thrombus, to yield a 
thin rim of neointima rather than a bulky mass causing 
stenosis. Local thrombus size limitation might be required so 
that patient safety could be maintained. These strategies are 
currently under evaluation in animal models (40). 
Conclusions. In summary, pharmacologic agents may 
have been ineffective against restenosis because the cellular 
and molecular events of restenosis remain poorly defined. 
An alternative hypothesis based on the porcine coronary 
injury model suggests that mural thrombus determines the 
volume of neointima early after angioplasty. Caution must 
be used before embarking on new, expensive and time-
consuming human trials. Strategies that are successful in 
some animal models should be confirmed in other models 
and species. Ideally, new human trials should be based on 
solid scientific understanding of proved mechanisms rather 
than on unconfirmed hypotheses. 
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